The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Neoadjuvant Chemotherapy plus Cystectomy Compared with Cystectomy Alone for Locally Advanced Bladder Cancer
Open accessAbstract
BACKGROUND: Despite aggressive local therapy, patients with locally advanced bladder cancer are at significant risk for metastases. We evaluated the ability of neoadjuvant chemotherapy to improve the outcome in patients with locally advanced bladder cancer who were treated with radical cystectomy. METHODS: Patients were enrolled if they had muscle-invasive bladder cancer (stage T2 to T4a) and were to be treated with radical cystectomy. They were stratified according to age (less than 65 years vs. 65 years or older) and stage (superficial muscle invasion vs. more extensive disease) and were randomly assigned to radical cystectomy alone or three cycles of methotrexate, vinblastine, doxorubicin, and cisplatin followed by radical cystectomy. RESULTS: We enrolled 317 patients over an 11-year period, 10 of whom were found to be ineligible; thus, 154 were assigned to receive surgery alone and 153 to receive combination therapy. According to an intention-to-treat analysis, the median survival among patients assigned to surgery alone was 46 months, as compared with 77 months among patients assigned to combination therapy (P=0.06 by a two-sided stratified log-rank test). In both groups, improved survival was associated with the absence of residual cancer in the cystectomy specimen. Significantly more patients in the combination-therapy group had no residual disease than patients in the cystectomy group (38 percent vs. 15 percent, P<0.001). CONCLUSIONS: As compared with radical cystectomy alone, the use of neoadjuvant methotrexate, vinblastine, doxorubicin, and cisplatin followed by radical cystectomy increases the likelihood of eliminating residual cancer in the cystectomy specimen and is associated with improved survival among patients with locally advanced bladder cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Greenlee, R. T., Hill-Harmon, M. B., Murray, T., & Thun, M. (2001) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.51.1.15 · Cited by 3,288
Pocock, S. J., & Simon, R. (1975) · Biometrics · doi:10.2307/2529712 · Cited by 2,350
Loehrer, P. J., Einhorn, L. H., Elson, P. J., Crawford, E. D., Kuebler, P., Tannock, I., Raghavan, D., Stuart-Harris, R., Sarosdy, M. F., & Lowe, B. A. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.7.1066 · Cited by 981
Self-citationSternberg, C. N., Yagoda, A., Scher, H. I., Watson, R. C., Ahmed, T., Weiselberg, L. R., Geller, N., Hollander, P. S., Herr, H. W., Sogani, P. C., et al. (1985) · Journal of Urology · doi:10.1016/s0022-5347(17)48996-8 · Cited by 654
Logothetis, C. J., Dexeus, F. H., Finn, L., Sella, A., Amato, R. J., Ayala, A. G., & Kilbourn, R. G. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.6.1050 · Cited by 607
Millikan, R., Dinney, C., Swanson, D., Sweeney, P., Ro, J. Y., Smith, T. L., Williams, D., & Logothetis, C. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.20.4005 · Cited by 271
Neoadjuvant chemotherapy and bladder-sparing surgery for invasive bladder cancer: ten-year outcome.
Herr, H. W., Bajorin, D. F., & Scher, H. I. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.4.1298 · Cited by 203
Cited by
Lenis, A. T., Lec, P. M., Chamie, K., & MSHS, M. (2020) · JAMA · doi:10.1001/jama.2020.17598 · Cited by 2,051
Witjes, J. A., Bruins, H. M., Cathomas, R., Compérat, E. M., Cowan, N. C., Gakis, G., Hernández, V., Linares Espinós, E., Lorch, A., Neuzillet, Y., et al. (2021) · European Urology · doi:10.1016/j.eururo.2020.03.055 · Cited by 2,017
Choi, W., Porten, S., Kim, S., Willis, D., Plimack, E. R., Hoffman-Censits, J., Roth, B., Cheng, T., Tran, M., Lee, I.-L., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.01.009 · Cited by 1,716
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Kamat, A. M., Hahn, N. M., Efstathiou, J. A., Lerner, S. P., Malmström, P.-U., Choi, W., Guo, C. C., Lotan, Y., & Kassouf, W. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30512-8 · Cited by 1,421
Vale, C. L. (2005) · European Urology · doi:10.1016/j.eururo.2005.04.006 · Cited by 1,325
Treatment of muscle‐invasive and advanced bladder cancer in 2020
Patel, V. G., Oh, W. K., & Galsky, M. D. (2020) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21631 · Cited by 1,014
Kaufman, D. S., Shipley, W. U., & Feldman, A. S. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60491-8 · Cited by 988
Radiotherapy with or without Chemotherapy in Muscle-Invasive Bladder Cancer
James, N. D., Hussain, S. A., Hall, E., Jenkins, P., Tremlett, J., Rawlings, C., Crundwell, M., Sizer, B., Sreenivasan, T., Hendron, C., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1106106 · Cited by 962
International Collaboration of Trialists on behalf of the Medical Research Council Advanced Bladder Cancer Working Party (now the National Cancer Research Institute Bladder Cancer Clinical Studies Group), T. E. O. F. R. A. T. O. C. G.-U. T. C. G. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.3139 · Cited by 949
Neoadjuvant-adjuvant or adjuvant-only pembrolizumab in advanced melanoma
Patel, S. P., Othus, M., Chen, Y., Wright, G. P., Yost, K. J., Hyngstrom, J. R., Hu-Lieskovan, S., Lao, C. D., Fecher, L. A., Truong, T.-G., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2211437 · Cited by 919
Tumor Evolution and Drug Response in Patient-Derived Organoid Models of Bladder Cancer
Lee, S. H., Hu, W., Matulay, J. T., Silva, M. V., Owczarek, T. B., Kim, K., Chua, C. W., Barlow, L. J., Kandoth, C., Williams, A. B., et al. (2018) · Cell · doi:10.1016/j.cell.2018.03.017 · Cited by 873
Seiler, R., Ashab, H. A. D., Erho, N., van Rhijn, B. W. G., Winters, B., Douglas, J., Van Kessel, K. E., Fransen van de Putte, E. E., Sommerlad, M., Wang, N. Q., et al. (2017) · European Urology · doi:10.1016/j.eururo.2017.03.030 · Cited by 786
Treatment of Muscle-invasive and Metastatic Bladder Cancer: Update of the EAU Guidelines
Stenzl, A., Cowan, N. C., De Santis, M., Kuczyk, M. A., Merseburger, A. S., Ribal, M. J., Sherif, A., & Witjes, J. A. (2011) · European Urology · doi:10.1016/j.eururo.2011.03.023 · Cited by 677
Panebianco, V., Narumi, Y., Altun, E., Bochner, B. H., Efstathiou, J. A., Hafeez, S., Huddart, R., Kennish, S., Lerner, S., Montironi, R., et al. (2018) · European Urology · doi:10.1016/j.eururo.2018.04.029 · Cited by 658
The Updated EAU Guidelines on Muscle-Invasive and Metastatic Bladder Cancer
Stenzl, A., Cowan, N. C., De Santis, M., Jakse, G., Kuczyk, M. A., Merseburger, A. S., Ribal, M. J., Sherif, A., & Witjes, J. A. (2009) · European Urology · doi:10.1016/j.eururo.2009.01.002 · Cited by 639
Somatic ERCC2 Mutations Correlate with Cisplatin Sensitivity in Muscle-Invasive Urothelial Carcinoma
Van Allen, E. M., Mouw, K. W., Kim, P., Iyer, G., Wagle, N., Al-Ahmadie, H., Zhu, C., Ostrovnaya, I., Kryukov, G. V., O'Connor, K. W., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0623 · Cited by 620
Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Powles, T., Bellmunt, J., Comperat, E., De Santis, M., Huddart, R., Loriot, Y., Necchi, A., Valderrama, B. P., Ravaud, A., Shariat, S. F., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2021.11.012 · Cited by 555
Dyrskjøt, L., Hansel, D. E., Efstathiou, J. A., Knowles, M. A., Galsky, M. D., Teoh, J., & Theodorescu, D. (2023) · Nature Reviews Disease Primers · doi:10.1038/s41572-023-00468-9 · Cited by 544
Plimack, E. R., Dunbrack, R. L., Brennan, T. A., Andrake, M. D., Zhou, Y., Serebriiskii, I. G., Slifker, M., Alpaugh, K., Dulaimi, E., Palma, N., et al. (2015) · European Urology · doi:10.1016/j.eururo.2015.07.009 · Cited by 519
Yin, M., Joshi, M., Meijer, R. P., Glantz, M., Holder, S., Harvey, H. A., Kaag, M., Fransen van de Putte, E. E., Horenblas, S., & Drabick, J. J. (2016) · The Oncologist · doi:10.1634/theoncologist.2015-0440 · Cited by 474
Mak, R. H., Hunt, D., Shipley, W. U., Efstathiou, J. A., Tester, W. J., Hagan, M. P., Kaufman, D. S., Heney, N. M., & Zietman, A. L. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.5548 · Cited by 465
Efstathiou, J. A., Spiegel, D. Y., Shipley, W. U., Heney, N. M., Kaufman, D. S., Niemierko, A., Coen, J. J., Skowronski, R. Y., Paly, J. J., McGovern, F. J., et al. (2012) · European Urology · doi:10.1016/j.eururo.2011.11.010 · Cited by 435
Dash, A., Galsky, M. D., Vickers, A. J., Serio, A. M., Koppie, T. M., Dalbagni, G., & Bochner, B. H. (2006) · Cancer · doi:10.1002/cncr.22031 · Cited by 435
Bellmunt, J., Hussain, M., Gschwend, J. E., Albers, P., Oudard, S., Castellano, D., Daneshmand, S., Nishiyama, H., Majchrowicz, M., Degaonkar, V., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00004-8 · Cited by 429
Gakis, G., Efstathiou, J., Lerner, S. P., Cookson, M. S., Keegan, K. A., Guru, K. A., Shipley, W. U., Heidenreich, A., Schoenberg, M. P., Sagaloswky, A. I., et al. (2013) · European Urology · doi:10.1016/j.eururo.2012.08.009 · Cited by 422
Sternberg, C. N., Skoneczna, I., Kerst, J. M., Albers, P., Fossa, S. D., Agerbaek, M., Dumez, H., de Santis, M., Théodore, C., Leahy, M. G., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71160-x · Cited by 389
The effect of age and gender on bladder cancer: a critical review of the literature
Shariat, S. F., Sfakianos, J. P., Droller, M. J., Karakiewicz, P. I., Meryn, S., & Bochner, B. H. (2010) · BJU International · doi:10.1111/j.1464-410x.2009.09076.x · Cited by 371
Raman, J. D., Messer, J., Sielatycki, J. A., & Hollenbeak, C. S. (2011) · BJU International · doi:10.1111/j.1464-410x.2010.09675.x · Cited by 364
Ploussard, G., Daneshmand, S., Efstathiou, J. A., Herr, H. W., James, N. D., Rödel, C. M., Shariat, S. F., Shipley, W. U., Sternberg, C. N., Thalmann, G. N., et al. (2014) · European Urology · doi:10.1016/j.eururo.2014.02.038 · Cited by 355
A framework for the development of effective anti-metastatic agents
Anderson, R. L., Balasas, T., Callaghan, J., Coombes, R. C., Evans, J., Hall, J. A., Kinrade, S., Jones, D., Jones, P. S., Jones, R., et al. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0134-8 · Cited by 341
Bladder Cancer in 2010: How Far have We Come?
Jacobs, B. L., Lee, C. T., & Montie, J. E. (2010) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20077 · Cited by 336
Radiotherapy With Concurrent Carbogen and Nicotinamide in Bladder Carcinoma
Hoskin, P. J., Rojas, A. M., Bentzen, S. M., & Saunders, M. I. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.4950 · Cited by 332
Petrelli, F., Coinu, A., Cabiddu, M., Ghilardi, M., Vavassori, I., & Barni, S. (2014) · European Urology · doi:10.1016/j.eururo.2013.06.049 · Cited by 331
Gao, J., Navai, N., Alhalabi, O., Siefker-Radtke, A., Campbell, M. T., Tidwell, R. S., Guo, C. C., Kamat, A. M., Matin, S. F., Araujo, J. C., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-1086-y · Cited by 318
Clark, P. E., Agarwal, N., Biagioli, M. C., Eisenberger, M. A., Greenberg, R. E., Herr, H. W., Inman, B. A., Kuban, D. A., Kuzel, T. M., Lele, S. M., et al. (2013) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2013.0059 · Cited by 317
Self-citationKulkarni, G. S., Hermanns, T., Wei, Y., Bhindi, B., Satkunasivam, R., Athanasopoulos, P., Bostrom, P. J., Kuk, C., Li, K., Templeton, A. J., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.69.2327 · Cited by 313
Nikolos, F., Hayashi, K., Hoi, X. P., Alonzo, M. E., Mo, Q., Kasabyan, A., Furuya, H., Trepel, J., Di Vizio, D., Guarnerio, J., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29026-9 · Cited by 312
Tarhini, A. A., Edington, H., Butterfield, L. H., Lin, Y., Shuai, Y., Tawbi, H., Sander, C., Yin, Y., Holtzman, M., Johnson, J., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0087705 · Cited by 310
Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer
Choi, W., Czerniak, B., Ochoa, A., Su, X., Siefker-Radtke, A., Dinney, C., & McConkey, D. J. (2014) · Nature Reviews Urology · doi:10.1038/nrurol.2014.129 · Cited by 302
Rosenblatt, R., Sherif, A., Rintala, E., Wahlqvist, R., Ullén, A., Nilsson, S., & Malmström, P.-U. (2012) · European Urology · doi:10.1016/j.eururo.2011.12.010 · Cited by 294
Multicenter Assessment of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer
Zargar, H., Espiritu, P. N., Fairey, A. S., Mertens, L. S., Dinney, C. P., Mir, M. C., Krabbe, L.-M., Cookson, M. S., Jacobsen, N.-E., Gandhi, N. M., et al. (2015) · European Urology · doi:10.1016/j.eururo.2014.09.007 · Cited by 294
TERT promoter mutations and telomerase reactivation in urothelial cancer
Borah, S., Xi, L., Zaug, A. J., Powell, N. M., Dancik, G. M., Cohen, S. B., Costello, J. C., Theodorescu, D., & Cech, T. R. (2015) · Science · doi:10.1126/science.1260200 · Cited by 292
Dinney, C. P. N., McConkey, D. J., Millikan, R. E., Wu, X., Bar-Eli, M., Adam, L., Kamat, A. M., Siefker-Radtke, A. O., Tuziak, T., Sabichi, A. L., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.08.002 · Cited by 290
Self-citationKaag, M. G., O'Malley, R. L., O'Malley, P., Godoy, G., Chen, M., Smaldone, M. C., Hrebinko, R. L., Raman, J. D., Bochner, B., Dalbagni, G., et al. (2010) · European Urology · doi:10.1016/j.eururo.2010.06.029 · Cited by 289
Plimack, E. R., Hoffman-Censits, J. H., Viterbo, R., Trabulsi, E. J., Ross, E. A., Greenberg, R. E., Chen, D. Y. T., Lallas, C. D., Wong, Y.-N., Lin, J., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.2465 · Cited by 287
McConkey, D. J., Choi, W., Shen, Y., Lee, I.-L., Porten, S., Matin, S. F., Kamat, A. M., Corn, P., Millikan, R. E., Dinney, C., et al. (2016) · European Urology · doi:10.1016/j.eururo.2015.08.034 · Cited by 277
Boorjian, S. A., Sheinin, Y., Crispen, P. L., Farmer, S. A., Lohse, C. M., Kuntz, S. M., Leibovich, B. C., Kwon, E. D., & Frank, I. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0731 · Cited by 270
Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology
Spiess, P. E., Agarwal, N., Bangs, R., Boorjian, S. A., Buyyounouski, M. K., Clark, P. E., Downs, T. M., Efstathiou, J. A., Flaig, T. W., Friedlander, T., et al. (2017) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.0156 · Cited by 268
Prognostic and Prediction Tools in Bladder Cancer: A Comprehensive Review of the Literature
Kluth, L. A., Black, P. C., Bochner, B. H., Catto, J., Lerner, S. P., Stenzl, A., Sylvester, R., Vickers, A. J., Xylinas, E., & Shariat, S. F. (2015) · European Urology · doi:10.1016/j.eururo.2015.01.032 · Cited by 265
Nomograms Provide Improved Accuracy for Predicting Survival after Radical Cystectomy
Shariat, S. F., Karakiewicz, P. I., Palapattu, G. S., Amiel, G. E., Lotan, Y., Rogers, C. G., Vazina, A., Bastian, P. J., Gupta, A., Sagalowsky, A. I., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0372 · Cited by 263
Dash, A., Pettus, J. A., Herr, H. W., Bochner, B. H., Dalbagni, G., Donat, S. M., Russo, P., Boyle, M. G., Milowsky, M. I., & Bajorin, D. F. (2008) · Cancer · doi:10.1002/cncr.23848 · Cited by 258
Donat, S. M., Shabsigh, A., Savage, C., Cronin, A. M., Bochner, B. H., Dalbagni, G., Herr, H. W., & Milowsky, M. I. (2009) · European Urology · doi:10.1016/j.eururo.2008.07.018 · Cited by 252
Clinical therapies and nano drug delivery systems for urinary bladder cancer
Jain, P., Kathuria, H., & Momin, M. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107871 · Cited by 89
Clinical benefit of neoadjuvant anti‐PD‐1/PD‐L1 utilization among different tumors
Li, Z., Wu, X., Zhao, Y., Xiao, Y., Zhao, Y., Zhang, T., Li, H., Sha, F., Wang, Y., Deng, L., et al. (2021) · MedComm · doi:10.1002/mco2.61 · Cited by 23
Metadata
- Authors
- Grossman, H. B., Natale, R. B., Tangen, C. M., Speights, V. O., Vogelzang, N. J., Trump, D. L., White, R. W. D., Sarosdy, M. F., Wood, D. P., Raghavan, D., & Crawford, E. D.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2003-08-28
- Volume
- 349
- Issue
- 9
- Pages
- 859-866
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1975918912
- Cited by
- 2,668
- References
- 9
- FWCI
- 43.87
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.